ReviewJournal of anaesthesiology, clinical pharmacology
Clinical enigma: Case-based systematic review of flumazenil in the management of paradoxical reactions to midazolam - A quarter-century perspective.
Review in Journal of anaesthesiology, clinical pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The mechanism of paradoxical reaction is still a big question for the medical world, but several theoretical approaches have arisen. Midazolam, a high-potency benzodiazepine, carries a higher risk of paradoxical reaction. Paradoxical reactions associated with midazolam are often misunderstood and mismanaged, with clinicians frequently attributing them to factors like inadequate dosing or low sedation levels. This leads to the common practice of escalating midazolam dosage or exploring alternative sedatives, despite flumazenil offering a safer solution theoretically. Flumazenil emerges as a viable antidote as it swiftly and effectively reverses paradoxical reactions, proving to be a safer alternative to dose escalation strategies. Material and Methods: In this systematic review, we conducted a search regarding the use of flumazenil in midazolam-induced paradoxical reactions over a quarter-century period (1998-2023) in three databases. We include 10 case reports presenting a total of 14 cases, which adhered to the specified inclusion criteria. Result: We selected 10 case reports published from 1998 to 2023 with a total of 14 cases. Study characteristics, patient demographics, midazolam dose and administration route, incident of paradoxical effect, flumazenil dose and administration route, and outcome of flumazenil administration. Conclusions: All the cases showed the prosperous effectiveness of flumazenil in reducing paradoxical reaction symptoms with no adverse effect on hemodynamics. Ongoing research and study in this field are essential to refine protocols and enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.